Amendment 3 to RFP 75D301-22-R-72483.pdf

AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT

1. CONTRACT ID CODE

PAGE OF PAGES

1 2

2. AMENDMENT/MODIFICATION NO.

00003

3. EFFECTIVE DATE

12/01/2022

4. REQUISITION/PURCHASE REQ. NO.

5. PROJECT NO. (If applicable)

6. ISSUED BY CODE 7. ADMINISTERED BY (If other than Item 6) CODE Centers for Disease Control and Prevention

(CDC)

Office of Acquisition Services (OAS) 2900 Woodcock Blvd, MS TCU-4 Atlanta GA 303414004

8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code)

X

9A. AMENDMENT OF SOLICITATION NO.

75D301-22-R-72483

9B. DATED (See Item 11)

11/15/2022

10A. MODIFICATION OF CONTRACT/ORDER NO.

10B. DATED (See Item 13)

CODE FACILITY CODE

11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS

X The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers is extended, X is not extended.

Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods:

(a) By completing Items 8 and 15, and returning 1 copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

12. ACCOUNTING AND APPROPRIATION DATA (If required)

13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS,

IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN

B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).

C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:

D. OTHER (Specify type of modification and authority)

E. IMPORTANT: Contractor is not, is required to sign this document and return copies to the issuing office.

14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)

The purpose of this amendment is to clarify that CDC seeks to award contracts for all U.S.-licensed or authorized COVID-19 vaccine brands with an adult indication, as shown through tracked changes to section B.1 on page 2 of this amendment.

All other terms and conditions remain unchanged. The due date for proposals remains 5:00 pm ET on December 5, 2022.

Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.

15A. NAME AND TITLE OF SIGNER (Type or print)

16A. NAME OF CONTRACTING OFFICER

15B. CONTRACTOR/OFFEROR

(Signature of person authorized to sign)

15C. DATE SIGNED

16B. UNITED STATES OF AMERICA

BY ___________________________________________

(Signature of Contracting Officer)

16C. DATE SIGNED

NSN 7540-01-152-8070 STANDARD FORM 30 (REV. 10-83)

PREVIOUS EDITION UNUSABLE 30-105 Prescribed by GSA

FAR (48 CFR) 53.243

ITEM 10A.

75D301-22-R-72483 00003

Section B.1:

B.1 Background

The Centers for Disease Control and Prevention (CDC) is seeking to award one or more indefinite delivery/indefinite quantity (IDIQ) contracts for the purchase of standard commercial adult vaccines.

CDC seeks to award contracts for all U.S.-licensed or authorized COVID-19 vaccine brands with an adult indication. Awarding contracts for all U.S.-licensed or authorized COVID-19 vaccines provides greater provider brand choice, a fundamental principle of CDC’s immunization program, which puts the decision about which vaccine should be administered to an individual patient into the hands of the provider, who is in the best position to determine what is most appropriate for that patient. Awarding contracts for all U.S.-licensed or authorized COVID-19 vaccines also ensures a sufficient supply of vaccines to meet CDC program needs by making alternate products available if a vaccine product has manufacturing delays or supply shortages.

The establishment of these contracts provides opportunity to utilize Section 317 vaccine purchase funds to obtain vaccines at prices below those available in the commercial market place. These funds provide vaccines for state and local health departments to use in populations at greatest risk for under vaccination and disease. The 317 program, as established under Section 317(j) of the Public Health Service Act, works to ensure that adults receive appropriate immunization by partnering with healthcare providers in the public and private sectors. The program helps assure the implementation of effective immunization practices and proper use of vaccines to achieve higher immunization coverage. The vaccines awarded under these contracts will be purchased for the National Center for Immunization and Respiratory Disease’s (NCIRD’s) immunization awardees (the fifty state health departments, several large city programs and current and former U.S. Territories) to support adult immunization programs as provided under Section 317(j) of the Public Health Service Act. In addition, awardees may opt to purchase additional quantities of vaccine for adults under any resulting contract using state and local funds.